The The Role of Meteorin-Like Peptide and Asprosin in the Diagnosis of Endometrium Carcinoma
The Role Of Meteorin-Like Peptide And Asprosin
DOI:
https://doi.org/10.5281/zenodo.10020925Keywords:
Endometrium, adenocarcinoma, meteorin-like peptide, asprosinAbstract
Aim: Endometrial Carcinoma (EC) is one of the most common gynecological malignancies in developed countries and the diagnosis is generally suspected according to clinical and radiological findings and confirmed with pathological sampling. Immunohistochemical biomarkers have great importance in the diagnosis.
Materials and Methods: The patient samples that were obtained from the Pathology Laboratory of Fırat University Faculty of Medicine, Department of Pathology were used in this retrospective study. In this study, 30 patient samples were used. The control group consisted of healthy endometrial tissues of the same patient group. The other group consisted of tissues with Endometrial Adenocarcinoma (EAC) from the same patients. In all groups, the endometrial tissue samples were evaluated immunohistochemically with Meteorin-Like Peptide (METRNL) and Asprosin.
Results: Statistically significant differences were detected between the control and EAC groups in terms of METRNL and Asprosin.
Conclusion: The results of the present study show that there is a significant relationship between healthy endometrial tissue and EAC in terms of METRNL and Asprosin expression. Both markers are confirmed to have diagnostic values for EAC.
Downloads
References
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics,2021.CA Cancer J Clin 2021;71:7–33.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
Constantine GD, Kessler G, Graham S, Goldstein SR. Increased Incidence of Endometrial Cancer Following the Women’s Health Initiative: An Assessment of Risk Factors. J Womens Health (Larchmt) 2019;28:237–43.
Zhang S, Gong TT, Liu FH, et al. Global, Regional, and National Burden of Endometrial Cancer, 1990–2017: Results From the Global Burden of Disease Study, 2017. Front Oncol 2019;9:1440.
Allison KH, Reed SD, Voigt LF, Jordan CD, Newton KM, Garcia RL. Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol 2008;32:691–98.
Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update 2017;23:232–54.
Huang EC, Mutter GL, Crum CP, Nucci MR. Clinical outcome in diagnostically ambiguous foci of ‘gland crowding’ in the endometrium. Mod Pathol 2010;23:1486–91.
Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007;10:183–94.
Li ZY, Zheng SL, Wang P et al. Subfatin is a novel adipokine and unlike meteorin in adipose and brain expression. CNS Neurosci Ther 2014;20(4):344–54.
Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: A secreted protein with new emerging functions. Acta Pharmacol Sin 2016;37(5):571–9.
Li Z, Gao Z, Sun T et al. Meteorin-like/ Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: A comprehensive review of preclinical and clinical studies. Front. Immunol 2023;14:1098570.
Kerslake R, Hall M, Vagnarelli P, et al. A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer. Oncol Lett 2021;22(3):650.
Ovali MA, Bozgeyik I. Asprosin, a C‐terminal cleavage product of fibrillin 1 encoded by the FBN1 gene, in health and disease. Mol Syndromol 2022;13(3):175‐83.
Kocaman N, Yüksel EI, Demir B, Çalık İ, Çiçek D. Two Novel Biomarker Candidates for Differentiating Basal Cell Carcinoma from Trichoblastoma; Asprosin and Meteorine Like Peptide. Tissue Cell 2022;76:101752.
Akkuş G, Koyutürk LC, Yılmaz M, Hancer S, Özercan IH, Kuloğlu T. Asprosin and meteorin-like protein immunoreactivity in invasive ductal breast carcinoma stages. Tissue Cell 2022;77:101855.
Kocaman N, Artas G. Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma? Biotechnic & Histochemistry 2020;95:171-75.
Chen H, Strickland AL, Castrillon DH. Histopathologic diagnosis of endometrial precancers: updates and future directions. Semin Diagn Pathol 2022;39(3):137–47.
Yoon YS, Kwon AR, Lee YK, Oh SW. Circulating Adipokines and Risk of Obesity Related Cancers: A Systematic Review and Meta-Analysis. Obes Res Clin Pract 2019;13:329–39.
Doerstling SS, O’Flanagan CH, Hursting SD. Obesity and Cancer Metabolism: A Perspective on Interacting Tumor-Intrinsic and Extrinsic Factors. Front Oncol 2017;7:216.
Booth A, Magnuson A, Fouts J, Foster M. Adipose Tissue, Obesity and Adipokines: Role in Cancer Promotion. Horm Mol Biol Clin Investig 2015;21:57–74.
Balta H, Kocaman N. The Role of Meteorin-Like Peptide and TRPM2 in Differential Diagnosis in Benign, Premalignant and Malignant Lesions of the Endometrium. FU.Med J Health Sci 2023;3(1):50–55.
Manning AA, Zhao L, Zhu Z, et al. IL-39 acts as a friend to pancreatic cancer. Med Oncol 2018;36(1):12.
Jung T, Pyun DH, Kim TJ, et al. Meteorin-like protein [METRNL]/IL-41 improves LPS-induced inflammatory responses via AMPK or PPARδ–mediated signaling pathways. Adv Med Sci 2021;66:155-61.
Shivakumar M, Lee Y, Bang L, Garg T, Sohn KA, Kim D. Identification of epigenetic interactions between miRNA and DNA methylation associated with gene expression as potential prognostic markers in bladder cancer. BMC Medical Genomics 2017;10(Suppl 1):30.
Nam H, Kang S, Park MS, et al. A Serum Marker for Early Pancreatic Cancer with a Possible Link to Diabetes. J Natl Cancer Inst 2022;114(2):228-34.
Du C, Wang C, Guan X, et al. Asprosin is associated with anorexia and body fat mass in cancer patients. Support Care Cancer 2021;29(3):1369–75.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74.
Zhang Z, Tan Y, Zhu L, et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway. Life Sci 2019;231:116554.
Chen S, Wang X, Qiu CM, et al. Study of the Role and Mechanism of Asprosin/Spartin Pathway in Cardiac Microvascular Endothelial Injury Induced by Diabete Mellitus. Sichuan Da Xue Xue Bao Yi Xue Ban 2019;50(6):827–34.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Chronicles of Precision Medical Researchers
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
